What Spatz FGIA does

Spatz FGIA, Inc. is a U.S.-based medical device company headquartered in Great Neck, New York, focused on the development and commercialization of gastric balloon systems for non-surgical weight loss procedures. Founded in 2005, the company operates in the obesity treatment market alongside a small set of specialized competitors including Allurion Technologies, Apollo Endosurgery, and ReShape Lifesciences. Its core technology centers on advanced gastric balloon systems designed with improved safety and patient comfort characteristics compared to surgical bariatric alternatives, targeting healthcare providers and patients seeking minimally invasive obesity interventions.

The company employs between 51 and 100 people and is identified as a key market player actively investing in R&D to advance its product portfolio. Its proprietary focus is on the mechanical and clinical design of gastric balloon devices rather than software- or AI-driven capabilities. Distribution is presumed to follow the standard medical device model of selling to healthcare providers and clinical channels that administer the procedures to patients, though specific GTM mechanics, pricing, and reimbursement arrangements are not disclosed in the available data.

Spatz FGIA is a privately held company with no public ticker, no disclosed parent company, and no documented funding rounds. Operational data including revenue, ownership structure, management team, geographic footprint, and certification portfolio are not present in the provided sources, representing significant data gaps for any prospective investment diligence. The company's strategic posture as inferred from available evidence is that of a niche R&D-focused medical device specialist competing in a regulated, growing obesity treatment category.

Name

Spatz FGIA

Legal name

Spatz FGIA, Inc.

Website

https://spatzmedical.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Spatz FGIA is a U.S. medical device company developing gastric balloon systems for non-surgical weight loss procedures. Founded in 2005 and based in Great Neck, NY, it serves healthcare providers and patients seeking minimally invasive obesity treatments.

Ownership category

akta.pro rank

Headquarters

HQ city

Great Neck

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Core offering

Spatz FGIA develops and manufactures advanced gastric balloon medical devices for non-surgical weight loss procedures. The company's products are designed with improved safety and patient comfort features to address rising obesity rates. Spatz FGIA, Inc. operates as a key market player in the gastric balloon segment alongside competitors such as Allurion Technologies Inc., Apollo Endosurgery, Inc., and ReShape Lifesciences, Inc.

Product overview

Spatz FGIA is a medical device company focused on gastric balloon systems for non-surgical weight loss. The company develops advanced gastric balloon products designed to address obesity through minimally invasive procedures. Based on available information, Spatz FGIA operates in the gastric balloon market alongside competitors including Allurion Technologies Inc., Apollo Endosurgery, Inc., and ReShape Lifesciences, Inc.

Differentiator

Problem solved

Functional benefit

Products and services

• Advanced Gastric Balloon Systems

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Expansion highlights1 record

Broad incumbents

• Boston Scientific: Acquired Apollo Endosurgery, bringing scale, sales force, and R&D resources to the endoscopic bariatric and gastric balloon category — overlapping end market and clinician relationships with Spatz FGIA.
• Medtronic: Broad medtech incumbent with metabolic/obesity franchise (including bariatric surgery and emerging diabetes/weight-loss adjacencies). Overlaps with Spatz FGIA in the obesity-treatment end market.
• Johnson & Johnson (Ethicon): Major surgical and bariatric stapling franchise through Ethicon, targeting the same obesity-treatment patient population — though via surgical rather than endoscopic approaches.

Direct peers

• Allurion Technologies: Direct competitor in the gastric balloon space, offering the Allurion (Elipse) swallowable, procedure-less balloon for non-surgical weight loss — directly comparable product and patient population to Spatz FGIA.
• ReShape Lifesciences: Direct competitor with a gastric balloon product (formerly ReShape and Obalon) targeting the same non-surgical weight-loss market as Spatz FGIA.
• Apollo Endosurgery: Direct competitor in gastric balloons (Orbera) and endoscopic bariatric devices, now part of Boston Scientific. Competes with Spatz FGIA in the same procedure category and patient base.

Emerging players

• GI Dynamics: Developer of the EndoBarrier gastrointestinal liner for non-surgical weight loss and type 2 diabetes. Targets an overlapping patient population and minimally invasive obesity-treatment category.
• USGI Medical: Developer of endoscopic incisionless surgery tools used in bariatric and GI procedures — adjacent technology serving the same non-surgical obesity-treatment patient population as Spatz FGIA.
• BAROnova: Developer of the TransPyloric Shuttle, an endoscopic device for weight loss. Competes in the same non-surgical endoscopic obesity-treatment category as Spatz FGIA.
• Aspire Bariatrics: Developer of the AspireAssist aspiration therapy for non-surgical weight loss. Addresses the same obesity-treatment patient population as Spatz FGIA via a different minimally invasive mechanism.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spatz FGIA